Ultralife Corporation Reports Third Quarter Results

ULTRALIFE CORP (ULBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ultralife Corporation Reports Third Quarter Results NEWARK, N.Y. – November 5, 2026 -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the third quarter ended September 30, 2026 with the following results: ● Sales of $48.3 million compared to $43.

Event · Earnings
Original reporting
Published Nov 9, 2026, 8:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ULBI
Bullish
high confidence
Mentioned
$ULBI
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ULBIBullishHigh
01

Why it matters

The earnings beat and acquisition announcement provide fresh, material information likely to move the stock.

02

Market read

First‑report earnings and a sizable M&A deal make this a high‑impact news item for ULBI and its sector.

03

What to watch

Potential dilution from the cash transaction and debt assumption may offset earnings upside.

Relevance 8/10Novelty 8/10Timing: today's release
AlphAI · Earnings readULBI · Q3 2026 · ended 2026-09-30

Ultralife Q3 2026 sales rose 11.3% to $48.3 million, operating income reached $3.2 million and backlog hit a record $136.0 million, with an all-cash EnerSys acquisition pending

✓Strong quarter

Sales grew 11.3% year over year, gross margin rose to 27.5% from 22.2%, operating income turned positive at $3,186 thousand against a prior-year loss, GAAP EPS was $0.14 against $(0.07), and backlog reached a stated record of $136.0 million. Offsetting factors are softness in commercial oil and gas sales, interest from the Electrochem financing, and the pending acquisition by EnerSys, under which the company will not hold a conference call.

Revenue
$48.3M
11.3% y/y
Battery & Energy Products
$45.1M
12.9% y/y
Gross margin · GAAP
27.5%
EPS · GAAP
$0.14

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenues (Q3 2026)GAAP$48.3M–11.3%
Total revenues, $ thousands (Q3 2026)GAAP$48.27M––
Battery & Energy Products sales (Q3 2026)GAAP$45.1M–12.9%
Battery & Energy Products sales, $ thousands (Q3 2026)GAAP$45.09M––
Communications Systems sales (Q3 2026)GAAP$3.2M–7.1% decrease
Communications Systems sales, $ thousands (Q3 2026)GAAP$3.18M––
Cost of products sold, total (Q3 2026)GAAP$34.98M––
Gross profit (Q3 2026)GAAP$13.3M––
Gross profit, $ thousands (Q3 2026)GAAP$13.29M––
Gross margin, % of revenue (Q3 2026)GAAP27.5%––
Battery & Energy Products gross margin (Q3 2026)GAAP26.7%––
Communications Systems gross margin (Q3 2026)GAAP40.1%––
Total operating expenses (Q3 2026)GAAP$10.1M––
Total operating expenses, $ thousands (Q3 2026)GAAP$10.11M––
Operating expenses, % of revenue (Q3 2026)GAAP20.9%––
Research and development (Q3 2026)GAAP$3.19M––
Selling, general and administrative (Q3 2026)GAAP$6.92M––
Operating income (loss) (Q3 2026)GAAP$3.2M––
Operating income (loss), $ thousands (Q3 2026)GAAP$3.19M––
Other expense (Q3 2026)GAAP$441K––
Income (loss) before income taxes (Q3 2026)GAAP$2.75M––
Income tax provision (benefit) (Q3 2026)GAAP$362K––
Net income (loss) attributable to Ultralife Corporation (Q3 2026)GAAP$2.37M––
GAAP diluted EPS (Q3 2026)GAAP$0.14––
GAAP basic EPS (Q3 2026)GAAP$0.14––
Adjusted EBITDA (Q3 2026)non-GAAP$5.6M––
Adjusted EBITDA, $ thousands (Q3 2026)non-GAAP$5.64M––
Adjusted EBITDA, % of sales (Q3 2026)non-GAAP11.7%––
Adjusted EBITDA, trailing twelve monthsnon-GAAP$20.7M––
Adjusted EBITDA, trailing twelve months, % of salesnon-GAAP10.8%––
Backlog (end of Q3 2026)other$136M––
Total revenues (nine months 2026)GAAP$143.7M––
Battery & Energy Products sales (nine months 2026)GAAP$133.4M––
Communications Systems sales (nine months 2026)GAAP$10.23M––
Gross profit (nine months 2026)GAAP$37.27M––
Research and development (nine months 2026)GAAP$9.38M––
Selling, general and administrative (nine months 2026)GAAP$21.49M––
Total operating expenses (nine months 2026)GAAP$30.86M––
Operating income (nine months 2026)GAAP$6.41M––
Other expense (nine months 2026)GAAP$1.34M––
Net income attributable to Ultralife Corporation (nine months 2026)GAAP$4.46M––
GAAP diluted EPS (nine months 2026)GAAP$0.27––
Adjusted EBITDA (nine months 2026)non-GAAP$14.99M––

Segments

SegmentRevenueq/qy/y
Battery & Energy ProductsCompany explanation: the increase reflects 56.7% growth in government/defense sales, due primarily to a large order for conformal wearable batteries, partly offset by a 5.8% decrease in commercial sales, primarily due to softness in the global oil & gas market. Gross margin rose to 26.7% from 22.1%, which the company attributes primarily to progress in improving manufacturing efficiencies and vertical integration of its thionyl-chloride cells, as well as favorable product mix.$45.1M–12.9%
Communications SystemsThe release does not state a cause for the sales decline. Gross margin rose to 40.1% from 23.3%, which the company attributes primarily to lower warranty costs and sales mix.$3.2M–7.1% decrease
Government/defense sales (within Battery & Energy Products)Company explanation: growth due primarily to a large order for conformal wearable batteries.Not printed in dollars–56.7%
Commercial sales (within Battery & Energy Products)Company explanation: primarily due to softness in the global oil & gas market.Not printed in dollars–5.8% decrease

Capital returns

  • The release does not report share repurchases or cash dividends for the quarter or the nine months.
  • Weighted average diluted shares were 16,697 thousand in Q3 2026 against 16,646 thousand in Q3 2025.

What drove it

  • Company explanation: Battery & Energy Products government/defense sales grew 56.7%, due primarily to a large order for conformal wearable batteries.
  • Company explanation: Battery & Energy Products gross margin improved to 26.7% from 22.1%, primarily due to progress in manufacturing efficiencies and vertical integration of thionyl-chloride cells, as well as favorable product mix.
  • Company explanation: Communications Systems gross margin improved to 40.1% from 23.3%, primarily due to lower warranty costs and sales mix.
  • Operating expenses were $10.1 million against $10.6 million. The release cites higher new product development costs, offset by a decrease in one-time, non-recurring costs of $0.6 million, which it says related primarily to the closing of the Calgary facility and certain consulting costs in the prior-year quarter.
  • Backlog reached $136.0 million, which the release describes as the highest level in the Company's history, against $117.5 million exiting Q2 2026 and $90.3 million exiting Q3 2025.

Concerns

  • Commercial battery sales fell 5.8%, which the company attributes primarily to softness in the global oil & gas market.
  • Communications Systems sales decreased 7.1% to $3.2 million, and the release gives no stated cause.
  • Other expense of $441 thousand comprises interest expense from the financing of the Electrochem acquisition, partly offset by the estimated portion of a refundable tax credit under the 45X Advanced Manufacturing Production Tax Credit.
  • On October 27, 2026, Ultralife agreed to be acquired by EnerSys (NYSE: ENS) in an all-cash transaction valued at approximately $320 million, including the assumption of net debt. The transaction is expected to close in the first quarter of 2027.
  • Because of the pending transaction, Ultralife will not hold a conference call on the third quarter results.

What to watch

  • Closing of the EnerSys acquisition, expected in the first quarter of 2027.
  • Conversion of the $136.0 million backlog into revenue.
  • Whether gross margin holds near 27.5% in future periods, given the company's explanation of manufacturing and mix gains.
  • Commercial oil & gas demand, given the 5.8% decline in commercial battery sales.
  • Level of other expense as the Electrochem acquisition financing and the 45X tax credit continue.

Balance sheet and cash flow

  • Cash was $8,628 thousand at September 30, 2026 against $9,345 thousand at December 31, 2025.
  • Inventories, net were $62,314 thousand against $54,008 thousand at December 31, 2025.
  • Trade accounts receivable, net were $35,790 thousand against $33,948 thousand at December 31, 2025.
  • Current portion of long-term debt was $3,125 thousand against $4,125 thousand at December 31, 2025.
  • Long-term debt, net was $47,393 thousand against $45,526 thousand at December 31, 2025.
  • Total assets were $224,403 thousand against $216,912 thousand at December 31, 2025.
  • Total Ultralife equity was $134,528 thousand against $129,995 thousand at December 31, 2025.
  • The release does not report operating cash flow or free cash flow.

Analysis

Ultralife reported third quarter 2026 total revenues of $48.3 million, up 11.3% from $43.4 million, with growth concentrated in Battery & Energy Products, which rose 12.9% to $45.1 million. Within that segment, government/defense sales grew 56.7%, which the company attributes primarily to a large order for conformal wearable batteries. Commercial sales fell 5.8%, which the company attributes primarily to softness in the global oil & gas market. Communications Systems sales declined 7.1% to $3.2 million, and the release gives no cause for that decline.

Profitability improved sharply. Gross profit rose to $13.3 million, or 27.5% of revenue, from $9.6 million, or 22.2%. Battery & Energy Products gross margin reached 26.7% against 22.1%, and Communications Systems gross margin reached 40.1% against 23.3%. The company attributes the Battery gain to manufacturing efficiencies, vertical integration of thionyl-chloride cells and product mix, and the Communications gain to lower warranty costs and sales mix. Operating expenses were $10.1 million, down from $10.6 million, with the release citing higher new product development costs offset by a $0.6 million decline in one-time costs. Operating income was $3,186 thousand against an operating loss of $(951) thousand a year earlier.

Below operating income, other expense was $441 thousand, down from $800 thousand, and the release describes it as mainly interest on the Electrochem acquisition financing, partly offset by the estimated third quarter portion of a 45X tax credit. Net income attributable to Ultralife was $2,368 thousand, or $0.14 per diluted share, against a loss of $(1,220) thousand, or $(0.07). Adjusted EBITDA, a non-GAAP measure, was $5.6 million, or 11.7% of sales, against $2.0 million, or 4.7%. Nine-month figures show the same direction, with operating income of $6,408 thousand against $4,704 thousand and GAAP diluted EPS of $0.27 against $0.09.

Backlog closed the quarter at $136.0 million, which the release calls the highest in company history, up from $117.5 million at the end of Q2 2026 and $90.3 million a year earlier. Cash fell to $8,628 thousand from $9,345 thousand at December 31, 2025, while inventories rose to $62,314 thousand from $54,008 thousand and long-term debt, net rose to $47,393 thousand from $45,526 thousand. The release provides no operating or free cash flow figures and gives no guidance.

The defining item is the agreement to be acquired by EnerSys in an all-cash transaction valued at approximately $320 million including assumed net debt, expected to close in the first quarter of 2027. The absence of a conference call and of any outlook means that the forward view rests on the backlog and the operating trend reported here.

Not in the filing

stated, not guessed
  • Prior-year and prior-quarter percentage changes for total revenue, gross profit, gross margin, operating income and EPS are not printed as such and are left null.
  • Q2 2026 quarterly revenue, gross profit and operating income are not printed in this release.
  • Segment operating income or segment adjusted EBITDA is not reported.
  • Communications Systems gross profit in dollars is not printed.
  • Operating cash flow and free cash flow are not reported.
  • Share repurchases and dividends are not reported.
  • Forward guidance for revenue, margins, operating expenses or tax rate is not provided.
  • Analyst consensus estimates and the share price reaction are not in the document.
  • No CFO commentary or executive quotes are included because the company will not hold a conference call.
  • Net debt amount is not separately printed; only the approximate $320 million transaction value including assumed net debt is given.
  • Trailing twelve-month adjusted EBITDA has no prior-period comparison printed.
  • The dollar amount of government/defense and commercial sales is not printed; only their percentage changes are given.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Ultralife Corp (NASDAQ: ULBI) filed an 8‑K reporting its Q3 2026 financials and disclosed a pending acquisition by EnerSys.

Company-level read

Ticker impact

$ULBIBullishHigh confidence
Context

Ultralife reported Q3 2026 results with revenue up 11.3% and announced a $320M all‑cash acquisition by EnerSys.

Expected impact

likely upward pressure as the market prices in the earnings beat and acquisition premium

Evidence & confidence

Revenue and operating income turned positive year‑over‑year, and the deal adds a cash premium, both fresh facts driving investor interest.

Market effects

Strengthens the defense‑battery niche and may lift peers in the energy‑storage sector.

Adds to positive sentiment for US‑listed defense and industrial manufacturers.

The EnerSys acquisition could influence global battery supply dynamics.

Counterpoint

Deal risk and integration challenges could weigh on ULBI if EnerSys overpays.

Key entities

  • Ultralife Corporation

    Battery and communications solutions provider reporting Q3 results.

  • EnerSys

    Acquirer offering $320M cash for ULBI.

Every ULBI earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$ENSHighAI 9/10

EnerSys to Buy Ultralife for $320 Million in Defense Expansion

EnerSys (ENS) will acquire Ultralife (ULBI) for $320M, paying $16/share, a 166% premium. The deal, expected to close Q1 2027, aims to expand EnerSys' defense battery business, adding manufacturing capacity and technologies. Ultralife generated $191M revenue in 2025. EnerSys expects $15-20M in annual cost savings and EPS growth post-acquisition.

$ULBIHighAI 8/10

Orders waiting to be filled at Ultralife hit $136 million, its highest level ever.

Ultralife Corporation (ULBI) reported Q3 2026 revenue of $48.3M, up from $43.4M in Q3 2025. Gross profit rose to $13.3M (27.5% of revenue) from $9.6M (22.2%). Operating income was $3.2M, reversing a $1.0M loss in the prior year. GAAP EPS was $0.14, compared to ($0.07). Adjusted EBITDA reached $5.6M, up from $2.0M. Backlog hit $136.0M, the highest ever. Ultralife also announced an agreement to be acquired by EnerSys (ENS) in an all-cash transaction.

$ULBIMed

Freedom: Ultralife upside after acquisition announcement is almost exhausted

Ultralife (ULBI) shares rose 145.4% to $15.61 after EnerSys (ENS) agreed to acquire it for $16 per share, a 166% premium. The deal, valued at $320M, is expected to close in Q1 2027. Analyst Vladimir Chernov sees limited upside for ULBI, with shares likely staying in the $15.5–16 range until the deal closes. ENS expects cost savings and EPS growth post-acquisition.